Clinical Trial Detail

NCT ID NCT04134325
Title Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

Hodgkin's lymphoma

Therapies

Nivolumab

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.